Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Wed 11 Nov 2009, 17:00 IMU - Imuniti Holdings Limited - South African Medical Research Council
IMU
IMU                                                                             
IMU - Imuniti Holdings Limited - South African Medical Research Council         
("MRC")Trials On Imuniti Wellness Pack                                          
IMUNITI HOLDINGS LIMITED                                                        
(Incorporated in the Republic of South Africa)                                  
(Registration number 2004/002282/06)                                            
(JSE Code: IMU & ISIN: ZAE000089199)                                            
("Imuniti" or "the Group")                                                      
SOUTH AFRICAN MEDICAL RESEARCH COUNCIL ("MRC")TRIALS ON IMUNITI WELLNESS PACK   
Further to the SENS announcement made on the 10 June 2009 in connection with    
the MRC Trials, the directors are pleased to advise shareholders that the       
Group has received the full report from the MRC regarding Phase I of the        
clinical trials conducted on the Imuniti Wellness Pack, a Herbal-Nutritional    
supplement with putative immune-modulating properties ("the Wellness Pack").    
Shareholders are reminded that the Phase 1 trials were in respect of the        
possible toxicity of the contents of the Wellness Pack and the MRC conclusion   
as set out below should be understood in this context:                          
"Overall in this study of healthy Study participants, there were no             
significant consistent changes in laboratory parameters over the 5 week study   
period in the groups receiving IMUNITI at different dosages. Furthermore,       
when compared to Study participants taking Placebo, Imuniti was subjectively    
well tolerated. No Study participant reported any side-effects. It is now       
necessary to carry out a safety and tolerability study in Study participants    
infected with the human immunodeficiency virus (HIV) and to determine the       
efficacy of IMUNITI as an immune modulating agent".                             
The directors are furthermore pleased to report that Phase II of the clinical   
trials has been approved by the MRC`s Ethics Committee. We quote from the       
letter received from the MRC:                                                   
"The next study, which is a Phase II placebo controlled efficacy study, to be   
conducted in KwaZulu-Natal in the VCT centres has been granted ethical          
approval. This study will recruit 100 HIV positive participants per site from   
the rural, and semi-urban and an urban VCT site".                               
Durban                                                                          
11 November 2009                                                                
Designated Advisor                                                              
Arcay Moela Sponsors (Proprietary) Limited                                      
(Registration number 2006/033725/07)                                            
Date: 11/11/2009 17:00:55 Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: